
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc is positioned for strong growth due to its innovative product pipeline and expanding market presence. The company has reiterated its full-year 2025 global revenue guidance for its first commercial product, ARIKAYCE, in the range of $405 million to $425 million, with projections for significant market expansion supported by a large volume of diagnosed patients and high misdiagnosis rates. Additionally, the anticipated launch of Brensocatib, which has generated considerable physician interest and is expected to capture a substantial market opportunity in bronchiectasis, further enhances the company's financial outlook.
Bears say
Insmed Inc. faces multiple risks that contribute to a negative outlook on its stock, including the potential for unexpected safety events or inadequate efficacy of its drug pipeline, which could hinder clinical trials and regulatory approval processes. The company reported substantial financial losses, with a net loss of $235.5 million for 4Q24 and a total of $913.8 million for FY24, raising concerns over its ability to sustain operations and fulfill debt obligations amid significant research and development expenses. Furthermore, challenges in commercialization, alongside possible delays and setbacks in product launches, may further diminish revenue generation prospects, reinforcing the negative sentiment.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares